Li Liu

Title: Li Liu - Innovator in Coronavirus Vaccine Development

Introduction

Li Liu is a prominent inventor based in Hong Kong, CN. He has made significant contributions to the field of immunology, particularly in the development of vaccines against coronavirus infections. His innovative work has garnered attention for its potential to enhance immunity in subjects at risk of or suffering from such infections.

Latest Patents

Li Liu holds 1 patent for his groundbreaking invention related to PD-1-based vaccines against coronavirus infection. This patent discloses soluble PD-1 (sPD-1) proteins and nucleic acids, along with therapeutic compositions that comprise these proteins and nucleic acids. The aim is to enhance the immunity of a subject against coronavirus infection. The invention includes soluble PD-1 fusion proteins that consist of a soluble PD-1 protein fragment and an antigenic protein fragment, which preferably includes a coronavirus protein fragment. In some embodiments, the coronavirus protein fragment is derived from a coronavirus receptor binding domain (RBD) or a coronavirus nucleoprotein (N). The sPD-1 proteins, nucleic acids, and compositions are formulated as a vaccine composition, and methods for treating subjects at risk of or suffering from coronavirus infection are also disclosed.

Career Highlights

Li Liu is associated with Versitech, Inc., where he continues to advance his research and development efforts. His work is pivotal in the ongoing fight against coronavirus, showcasing his commitment to public health and safety.

Collaborations

Li Liu collaborates with notable colleagues, including Zhiwei Chen and Kwok Yung Yuen, who contribute to his research endeavors and enhance the impact of his innovations.

Conclusion

Li Liu's contributions to the field of vaccine development, particularly against coronavirus, highlight his role as an influential inventor. His innovative approaches and collaborations are paving the way for advancements in immunology and public health.